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ine-Month Outcome of Patients Treated
y Percutaneous Coronary Interventions
or Bifurcation Lesions in the Recent Era
Report From the Prevention of Restenosis
ith Tranilast and its Outcomes (PRESTO) Trial
hilippe Garot, MD,* Thierry Lefèvre, MD,† Michael Savage, MD,‡ Yves Louvard, MD,*
illiam R. Bamlet, MS, James T. Willerson, MD,§ Marie-Claude Morice, MD,†
avid R. Holmes, JR, MD
uincy and Massy, France; Philadelphia, Pennsylvania; Houston, Texas; and Rochester, Minnesota
OBJECTIVES The aim of this research was to determine the influence of bifurcation lesions on the outcome
of patients undergoing percutaneous coronary intervention (PCI) in the recent era.
BACKGROUND The treatment of bifurcation lesions by PCI has been associated with an increased
complication rate. Whether recent improvements of interventional practice have translated
into improved outcomes in this patient subgroup is unknown.
METHODS The 11,482 patients enrolled in the Prevention of Restenosis with Tranilast and its Outcomes
(PRESTO) were stratified according to the presence (n  1,412) or absence (n  10,068) of
at least one bifurcation lesion treated by PCI. Baseline characteristics and outcome of patients
undergoing PCI for bifurcation lesions were compared to those of patients treated for
nonbifurcation lesions.
RESULTS Patients treated for bifurcation lesions were less likely to have prior myocardial infarction
(MI), prior coronary artery bypass graft surgery, and had a higher proportion of current stable
angina (p  0.01 for all comparisons). Bifurcation lesions involved more frequently the left
anterior descending coronary artery and were more complex (angulated, eccentric, ostial, and
tortuous) than nonbifurcation lesions. Percutaneous coronary intervention of bifurcation
lesions was characterized by less frequent stent implantation (71% vs. 80%); PCI of
bifurcation lesions was associated with an increased rate of combined end point death/MI/
target vessel revascularization (TVR) at nine months (18% vs. 15%, p  0.002) because of
increased rates of TVR (17% vs. 14%, p 0.001), whereas death (1%) and MI (1%) were not
different between groups.
CONCLUSIONS Percutaneous coronary intervention of bifurcation lesions is associated with higher TVR at
follow-up. However, the risk of death, MI, death/MI was similar in patients treated for
bifurcation or nonbifurcation lesions. (J Am Coll Cardiol 2005;46:606–12) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.065American College of Cardiology Foundation
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bhe success rate of bifurcation lesion percutaneous coronary
nterventions (PCI) has been reported to be lower with
igher incidence of procedural and periprocedural compli-
ations, including procedural-induced myocardial infarction
MI) and emergent coronary artery bypass graft (CABG)
urgery compared with nonbifurcation lesions (1,2). In
ddition, there are increased major adverse cardiac events
MACE) at one-year follow-up with reduced event-free
MI, CABG, and repeat coronary angioplasty) survival rates
n patients treated by PCI for bifurcation lesions compared
ith nonbifurcation lesions (1). However, this finding has
From the *Institut Cardio-vasculaire Paris Sud, Quincy and †Massy, France;
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; §Texas Heart
nstitute, Houston, Texas; and Mayo Clinic, Rochester, Minnesota. GlaxoSmith-
line provided financial support for important scientific, but nonproduct-related,
ublications based on data from the PRESTO trial. The PRESTO trial wasp
upported by grants from GlaxoSmithKline Pharmaceuticals.
Manuscript received December 17, 2004; accepted January 11, 2005.ot been consistently observed in unselected patients with
ifurcation lesions undergoing PCI (2).
The Prevention of Restenosis with Tranilast and its
utcomes (PRESTO) trial was designed to test the hy-
othesis that tranilast would reduce restenosis in patients
ndergoing PCI (3). Although the trial was negative (4), it
s the largest restenosis trial performed, with broad inclusion
nd limited exclusion criteria, and therefore affords a look at
ontemporary interventional practice. Using data from the
RESTO trial, we sought to evaluate the clinical and
ngiographic patient outcomes of bifurcation lesions treated
y PCI compared with those of nonbifurcation lesions.
ETHODS
he study design and outcome of the PRESTO trial have
een reported elsewhere (3). Briefly, the trial was a double-
lind, randomized (1:1:1:1:1) placebo-controlled trial of
atients undergoing successful PCI of at least one signifi-
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August 16, 2005:606–12 Outcome of Bifurcation Lesions PCIant lesion. Procedural success was defined by 50%
ngiographic residual stenosis without death, MI, or need
or CABG surgery before the first dose of study medication.
atients were randomly assigned to one of five arms: 1)
lacebo for three months twice a day; 2) 300 mg tranilast
rally twice a day for three months; 3) 450 mg tranilast
rally twice a day for three months; 4) 300 mg tranilast
rally twice a day for one month followed by two months of
lacebo; and 5) 450 mg tranilast orally twice a day for one
onth followed by two months of placebo. The primary end
oint of the study was the first occurrence of death, MI, or
schemia-driven target vessel revascularization (TVR)
ithin nine months of the PCI. For the present analysis,
atients enrolled in the PRESTO trial were stratified
ccording to presence or absence of at least one bifurcation
esion treated by PCI on the qualifying PCI. A bifurcation
esion was defined as a coronary stenosis involving a side
ranch 2.0 mm in reference diameter.
Table 1. Baseline Clinical Characteristics of Pa
Intervention According to Lesion Characteristi
Variables
Nonbifurca
(n 
Age 60.3
Male 7,79
Body mass index 28.3
Current stable angina 4,09
Ejection fraction, % 60.1
Current smoker 2,28
Hypertension 6,18
Dyslipidemia 6,54
Diabetes mellitus 2,36
Diabetes mellitus treatment
Diabetes, diet controlled only 55
Diabetes, insulin or oral agent 1,70
Prior MI 3,96
Prior unstable angina 3,06
Prior CABG 1,40
Prior PCI(s) 3,12
History of congestive heart failure 61
Peripheral vascular disease 61
Cerebrovascular accident 34
Baseline CRP, normal values 1,68
GP IIb/IIIa 3,60
Thrombolytics 42
Numbers in parentheses are percentages of the total.
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
MACE  major adverse cardiac events
MI  myocardial infarction
PRESTO  Prevention of Restenosis with Tranilast and
its Outcomes trial
SIRIUS  Study of the Sirolimus-Eluting Stent in the
Treatment of Patients with Long De Novo
Lesions in Small Native Coronary Arteries
TVR  target vessel revascularizationCABG  coronary artery bypass grafting; CRP  C-reactive pr
 percutaneous coronary intervention.tatistical methods. All baseline characteristics are re-
orted separately for patients treated by PCI for bifurcation
r nonbifurcation lesions, with continuous variables re-
orted as mean 1 SD and categorical variables reported as
ounts and percentages. Differences in baseline patient
haracteristics were assessed by using two-sample t tests for
ontinuous variables and chi-square tests for categorical
ariables. Logistic regression models were established to
nvestigate independent predictors of MACE (death, MI,
schemia-driven TVR) and TVR in patients with bifurca-
ion lesions. These models were adjusted for age, gender,
tudy center, and tranilast treatment group. Clinical and
rocedural characteristics with p  0.10 were entered in the
odels. Odds ratio with corresponding 95% confidence
ntervals are reported.
linical outcomes. The primary end point of the present
nalysis was to compare outcomes between patients under-
oing PCI of at least one bifurcation lesion and those with
onbifurcation lesions nine months after the index proce-
ure. The clinical outcome was defined as the composite
nd point of death, MI, or TVR. The secondary clinical end
oint was to compare outcome defined by the same com-
osite of events in the patients stratified as introduced
arlier at 30-day follow-up. Additional analyses considered
ach component of the combined end point separately at 9
onths and 30 days after the index PCI.
ngiographic outcomes. A protocol-driven angiography
ubstudy was prespecified in the main PRESTO trial and
ncluded 2,018 patients. For this analysis, angiographic
s Undergoing Percutaneous Coronary
ifurcation or Nonbifurcation Lesions)
Lesions
8)
One or More Bifurcation
Lesion (n  1,412) p Value
5 59.8  10.3 0.10
) 1,098 (78) 0.76
28.1  4.5 0.08
) 626 (44) 0.009
3 60.9  12.3 0.13
) 309 (22) 0.49
) 828 (59) 0.045
) 901 (64) 0.39
) 317 (23) 0.37
0.57
84 (6)
) 226 (16)
) 483 (34) 0.001
) 416 (29) 0.48
) 154 (11) 0.002
) 431 (31) 0.72
79 (6) 0.43
62 (4) 0.010
41 (3) 0.33
) 247 (74) 0.75
) 589 (42) 0.001
44 (3) 0.046tient
cs (B
tion
10,06
 10.
2 (77
 4.6
6 (41
 12.
6 (23
3 (61
3 (65
6 (24
8 (6)
2 (17
8 (39
0 (30
7 (14
0 (31
7 (6)
7 (6)
2 (3)
1 (72
2 (36
7 (4)otein; GP  glycoprotein; MI  myocardial infarction; PCI
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Outcome of Bifurcation Lesions PCI August 16, 2005:606–12utcomes were compared between patients undergoing PCI
or at least one bifurcation lesion and for nonbifurcation
esions. At initial coronary angiography, reference diameter,
inimal luminal diameter, and diameter stenosis were
ssessed in patients with bifurcation and nonbifurcation
esions. The acute gain was calculated as the difference
etween post- and pre-PCI minimal luminal diameter.
epeat coronary angiography in the angiographic substudy
as scheduled at nine-month follow-up, and the late loss
nd late loss index were compared in patients with bifurca-
ion and nonbifurcation lesions. Angiographic restenosis
as defined as 50% narrowing in the treated segment
worst stenosed lesion). The angiograms were analyzed by
wo laboratories using the cardiovascular measurement sys-
em (Medis Medical Imaging System, Leiden, the Nether-
ands) for quantitative measurements.
ESULTS
atient characteristics. A total of 1,412 patients treated by
CI for at least one bifurcation lesion (12.3% of the whole
tudy population) and 10,068 patients treated for nonbifur-
ation lesions were identified in the PRESTO database.
ompared with patients treated by PCI for nonbifurcation
esions, patients with bifurcation lesions had similar inci-
ence of diabetes, dyslipidemia, and current smoking. Pa-
ients with bifurcation lesions were less likely to have a
istory of MI (34% vs. 39%, p  0.001), less likely to have
rior CABG surgery (11% vs. 14%, p  0.002), and
Table 2. Angiographic Characteristics of Lesio
Intervention According to Bifurcation or Nonb
Variables
Nonbifurcation Les
(n  10,068)
Lesions treated per patient 1.4  0.6
Lesion length
10 mm 2,991 (30)
10–20 mm 5,791 (58)
20 mm 1,194 (12)
Lesion type (ACC/AHA)
Type A, B1, B2 8,365 (83)
Type C 1,689 (17)
Vessels treated
Circumflex 2,392 (24)
Left anterior descending 3,643 (36)
Right coronary artery 3,522 (35)
Other 511 (5)
Thrombus, n (%)
Definite 611 (6)
Possible 2,760 (28)
Angulation 45° 769 (8)
Calcified 1,560 (15)
Eccentric 4,807 (48)
De novo 8,592 (85)
In-stent restenosis 1,162 (12)
Irregular 3,048 (30)
Ostial 630 (6)
Occlusion 896 (9)
Tortuous 760 (8)Numbers in parentheses are percentages of the total.
ACC/AHA  American College of Cardiology/American Heavidence of peripheral vascular disease (4% vs. 6%, p 
.010), but more likely to have current stable angina (44%
s. 41%, p  0.009), whereas ejection fraction, a history of
ongestive heart failure, a history of prior acute coronary
yndromes, prior PCI, and prior cerebrovascular events were
omparable between groups (Table 1).
Compared with patients undergoing PCI for nonbifur-
ation lesions, patients treated for at least one bifurcation
esion were more likely to be treated in the left anterior
escending artery (Table 2), had worse angiographic lesion
haracteristics including angulation 45° (15% vs. 8%, p 
.001), de novo lesions (88% vs. 85%, p  0.020), eccentric
esions (52% vs. 48%, p 0.001), ostial lesions (15% vs. 6%,
 0.001), and tortuous lesions (9% vs. 8%, p  0.023).
tenting was less frequently used in patients with bifurca-
ion lesions (71% vs. 80%, p  0.001), but coronary
therectomy was more frequently used in these patients
Table 3). Patients with bifurcation lesions had 1.8  0.8
esions treated versus 1.4  0.6 for patients with nonbifur-
ation lesions (p  0.001), were more likely to have higher
ercent stenosis both before (88.4 9.4% vs. 87.2 10.4%,
 0.001) and after PCI (7.7  12.6% vs. 5.1  9.6%, p
0.001), as well as higher PCI-induced grades 1 to 4
issection (16% vs. 13%, p  0.005), thus leading to a
igher rate of failed PCI (1.4% vs. 0.4% for patients treated
or nonbifurcation lesions, p  0.001).
ACE during follow-up. Thirty-day adverse event rate
as relatively low, with similar low incidences of death
ndergoing Percutaneous Coronary
ation Lesions
One or More Bifurcation Lesion
(n  1,412) p Value
1.8  0.8 0.001
0.001
483 (35)
788 (56)
129 (9)
0.63
1,182 (84)
230 (16)
0.001
397 (28)
596 (42)
252 (18)
167 (12)
0.12
67 (5)
385 (27)
209 (15) 0.001
235 (17) 0.27
739 (52) 0.001
1,237 (88) 0.020
130 (9) 0.010
408 (29) 0.29
216 (15) 0.001
121 (9) 0.68
131 (9) 0.023ns U
ifurc
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August 16, 2005:606–12 Outcome of Bifurcation Lesions PCI1%, p  0.29), MI (1%, p  0.57), TVR (1%, p 
.11), and need for repeat coronary revascularization (1%, p
0.39) in patients undergoing PCI for bifurcation or
onbifurcation lesions. During subsequent follow-up, the
ombined end point death/MI/TVR was higher in patients
reated for bifurcation lesions (compared with patients
reated for nonbifurcation lesions) because of higher TVR
17% vs. 14%, p  0.001) and despite similar rates of death
1%), MI (1%), and death/MI (2%) (Table 4). Additionally,
atients with bifurcation lesions had a higher rate of
e-intervention by PTCA or CABG surgery (21% vs. 17%,
 0.001) at nine-month follow-up.
ngiographic results. Among the PRESTO patients en-
olled in the angiographic substudy (n  2,018), the
ostprocedural percent diameter stenosis was significantly
igher in patients treated by PCI for at least one bifurcation
esion with subsequent higher acute gain in patients with
onbifurcation lesions. However, the late loss (1.0  0.8 vs.
.0 0.8, p 0.96) and loss index (0.5 0.5 vs. 0.5 0.6,
Table 3. Type and Results of PCI Procedure o
Bifurcation or Nonbifurcation Lesions
Variables
Nonbifurca
(n 
PCI Procedure
Angiojet 1
Directional coronary atherectomy 7
Laser 7
Rotablator 38
Stent 8,05
Thrombectomy extraction catheter 2
Pre-PCI percent stenosis 87.2
Post-PCI percent stenosis 5.1
Pre-PCI TIMI flow grade
0–2 2,70
3 7,32
Post-PCI TIMI flow grade
0–2 8
3 9,96
Dissection grade code
0 8,68
1–4 1,32
Failed PCI 3
Numbers in parentheses are percentages of the total.
PCI  percutaneous coronary intervention; TIMI  Th
Table 4. Major Adverse Cardiac Events at Nin
Nonbifurcation Lesions
Variable/Event
Nonbifurcation Lesions
(n  10,068)
Death, MI, or TVR 1,499 (15)
Death or MI 247 (2)
Death 119 (1)
MI 141 (1)
TVR 1,367 (14)
PTCA 1,427 (14)
CABG 373 (4)
PTCA or CABG 1,711 (17)
Numbers in parentheses are percentages of the total.
CABG  coronary artery bypass grafting; MI  myocardial
angioplasty; TVR  target vessel revascularization. 0.44) were not different in patients with bifurcation or
onbifurcation lesions (Table 5). Although the late loss was
ot different between groups, the binary restenosis rate was
8% for patients treated for bifurcation lesions and 22% for
atients treated for nonbifurcation lesions (p  0.022).
ubsequent analysis of the group of patients treated for at
east one bifurcation lesion demonstrated that patients
ndergoing angiographic follow-up had higher rates of
VR (21% vs. 16%, p  0.028), repeat PTCA (26% vs.
3%, p  0.001), and PTCA/CABG (30% vs. 17%, p 
.001) compared with patients in whom the need for repeat
evascularization was driven by documented ischemia
spontaneous or induced by noninvasive tests) (Table 6).
redictors of MACE and TVR. After adjusting for age,
ender, study center, and tranilast treatment group in
atients treated for bifurcation lesions, lesions treated per
atient, diabetes mellitus, history of prior CABG, and
ransient ischemic attacks, as well as clinical presentation
angina status) were independently associated with an in-
sions Undergoing PCI According to
Lesions
8)
One or More Bifurcation
Lesion (n  1,412) p Value
) 1 (1) 0.68
) 20 (1.3) 0.008
10 (1) 0.88
73 (5) 0.015
1,008 (71) 0.001
) 1 (1) 0.25
.4 88.4  9.4 0.001
7.7  12.6 0.001
0.88
382 (27)
1,025 (73)
0.07
19 (1)
1,390 (99)
0.005
1,181 (84)
225 (16)
) 20 (1) 0.001
lysis In Myocardial Infarction.
onths According to Bifurcation or
One or More Bifurcation Lesion
(n  1,412) p Value
256 (18) 0.002
29 (2) 0.36
13 (1) 0.39
17 (1) 0.55
241 (17) 0.001
229 (16) 0.041
81 (6) 0.001
290 (21) 0.001f Le
tion
10,06
1 (1
4 (0.7
5 (1)
5 (4)
7 (80)
2 (1
 10
 9.6
5 (27)
6 (73)
6 (1)
1 (99)
9 (87)
9 (13)
7 (1e Minfarction; PTCA  percutaneous transluminal coronary
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Outcome of Bifurcation Lesions PCI August 16, 2005:606–12reased likelihood of MACE and TVR at follow-up.
onversely, use of stents and treatment of de novo lesions
ere associated with lower rates of MACE, whereas treat-
ent of restenosis lesions was an independent predictor of
VR at follow-up (Table 7).
ISCUSSION
n recent interventional practice, PCI of a bifurcation lesion
s not associated with increased MI/death rates at 30-day
nd 9-month follow-up. Compared with patients treated for
onbifurcation lesions, an increased rate of TVR and
eintervention is seen. The increase in TVR is, in part, the
esult of the so-called “oculo-stenotic reflex,” as patients in
he angiographic study had more frequent TVR compared
ith patients followed only clinically. This bias may influ-
nce the management and outcome of patients undergoing
CI, as previously described in the Belgium and Nether-
ands Stent (Benestent II) study (5). Additionally, patients
reated for bifurcation lesions had significantly more lesions
reated (1.8 vs. 1.4 per patient, p  0.001), which may
Table 5. QCA Lesion Characteristics for Ang
Lesion) (n  2,823 Lesions, 2,018 Patients)
Nonbifurcation Le
(n  2,474)
Before PCI
Percent diameter stenosis 73.8  16.2
Reference diameter 2.9  0.6
Minimal luminal
diameter
0.8  0.5
After PCI
Percent diameter stenosis 9.9  13.4
Reference diameter 3.0  0.5
Minimal luminal
diameter
2.7  0.6
Acute gain 1.9  0.7
Follow-up (nine-month)
50% loss of gain 798 (32)
Late loss 1.0  0.8
Late loss index 0.5  0.5
50% narrowing 551 (22)
Diameters in mm. Numbers in parentheses are percentages
PCI  percutaneous coronary intervention; QCA  qua
Table 6. Major Adverse Cardiac Events at Nin
According to Enrollment or Not in the Angio
Variables
Nonangiographic Sub
(n  1,063)
Death, MI, or TVR 183 (17)
Death or MI 26 (2)
Death 12 (1)
MI 15 (1)
TVR 168 (16)
PTCA 139 (13)
CABG 54 (5)
PTCA or CABG 186 (17)
Numbers in parentheses are percentages of the total. Nonhi
PTCA  percutaneous transluminal coronary angioplasty; TVR
Table 1.bviously have a significant impact on the rate of reinter-
entions.
ifurcation lesions, PCI, and outcomes. Treatment of
ifurcation lesions has been challenging. Indeed, specific
ifficulties involving access to the side branch and the
nowplow effect phenomenon have been identified even
efore the era of near-universal stenting. The procedural
uccess rate was consequently lower compared with that of
onbifurcation lesions (2,6–10). As a consequence, patients
ith bifurcation lesions were preferentially referred to car-
iac surgery until the late 1980s, and this strategy remains
ommon in many Western countries. Although superior to
hat of nonbifurcation lesions (37 of 10,068, 0.4%), the rate
f PCI failure was 20 of 1,412 procedures (1.4%) in the
tudy population, which contrasts with the 3% to 13% rates
f PCI failure reported in the literature (1,2,6–10). Re-
ently, Singh et al. (11) have reported, using the same
RESTO dataset, that in patients with restenosis on
ollow-up angiograms, 7% were treated for bifurcation
esions and 5% for nonbifurcation lesions (p  0.14). In
phic Substudy Patients (Worst Stenosed
One or More Bifurcation Lesion
(n  349) p Value
74.1  14.3 0.68
2.8  0.6 0.020
0.7  0.4 0.14
13.0  16.4 0.001
2.9  0.6 0.029
2.6  0.7 0.001
1.8  0.7 0.008
122 (35) 0.31
1.0  0.8 0.96
0.5  0.6 0.44
97 (28) 0.022
total.
ve coronary angiography.
onths in Patients With Bifurcation Lesions
ic Substudy
Angiographic Substudy
(n  349) p Value
73 (21) 0.12
3 (1) 0.07
1 (1) 0.15
2 (1) 0.21
73 (21) 0.028
90 (26) 0.001
27 (8) 0.06
104 (30) 0.001
cal ranking.iogra
sione M
graph
study
erarchi
 target vessel revascularization. Other abbreviations as in
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August 16, 2005:606–12 Outcome of Bifurcation Lesions PCIrder to avoid data duplication, this analysis was not
ncluded in the present paper. Furthermore, the TVR rate
as, although statistically higher, modestly increased in
atients treated for bifurcation lesions compared to that of
atients treated for nonbifurcation lesions (17% vs. 14%,
espectively, p  0.001). Additionally, this result needs to
e considered with regard to other obvious procedural
haracteristics influencing the rate of TVR that were more
requent in patients treated for bifurcation lesions (more
esions treated, more ostial lesions, lower stent use). Ac-
ording to the 13.2% TVR we recently reported in a large
rospective cohort (12), we found that the rate of TVR was
elatively low in patients treated for bifurcation lesions, close
o that of nonbifurcation lesions.
It is noteworthy that the strategy used to treat coronary
esions may obviously influence the outcome of PCI, and
his is specifically true in the management of bifurcation
esions. Actually, interventional strategies have been re-
ently developed to facilitate the approach to bifurcation
esions. The main difficulty in evaluating the efficacy of such
trategies results from inherent limitations of most pub-
ished registries including: the small populations of patients
eported, the retrospective design of the studies, the variety
f lesions types (“true” and “false” bifurcation), and tech-
iques that are usually incompletely or inadequately de-
cribed. Treatment of bifurcation lesions with debulking
echniques (directional and rotational atherectomy) without
tenting were variable, and stenting became the standard
trategy because of its scaffolding properties with the sub-
equent reduction of acute complications. The potential
enefit of debulking before stenting remains controversial
ecause some nonrandomized studies have suggested that
ebulking before stenting may be associated with lower
estenosis rates (13), whereas other reports suggested that
hese benefits were obtained at the cost of higher compli-
ation rates in patients treated by atherectomy and stenting
ersus patients treated by stenting alone, including higher
ates of postprocedure non–Q-wave MI (14). In the present
Table 7. Predictors of MACE and TVR at Fo
Variables
M
OR*
Baseline/medical history
characteristics
Lesions treated per patient 1.240
Diabetes mellitus 1.448
Prior CABG 1.627
Transient ischemic attacks 3.102
Current stable angina 1.819
PCI procedure
Stent 0.694
Lesion characteristics
De novo lesions 0.528
In-stent restenosis —
*Adjusted for age, gender, study center, and tranilast treatm
CI confidence interval; MACEmajor adverse cardiactudy, a debulking device (directional or rotational atherec- lomy) was used more frequently in patients treated for
ifurcation lesions (6.6% vs. 4.6% in patients treated for a
onbifurcation lesion), and this could have played a role in
he higher rates of PCI-induced dissections and failed
rocedures observed in patients treated for bifurcation
esions.
The main challenging issue with stenting in bifurcation
esions is to optimize stenting of the main branch while
reserving the side branch. To address this issue, data
ollected from bench test studies proved crucial, allowing
he understanding of stent behavior and the effects of
mpirically implemented strategies (15). In our experience
12), provisional T stenting of the side branch after system-
tic stenting of the main branch was the strategy associated
ith the lowest rate of MACE and TVR at follow-up when
ompared with strategies involving stenting of both main
nd side branches (Y, V, and T stenting strategies). The use
f drug-eluting stents has proven beneficial in dramatically
educing the rates of reintervention in unselected patients
ith de novo coronary lesions treated by PCI compared
ith bare metal stents (16). Despite technical improvements
n equipment and the experience acquired in many inter-
entionalist centers, stent placement in diabetic patients,
ong lesions, small vessels, and bifurcation stenoses is
ssociated with a restenosis rate that may exceed 50% (17).
he potential effect of drug-eluting stents in decreasing the
ates of MACE and reintervention after PCI of bifurcation
esions has been recently published by Colombo et al. (18),
ho reported an improvement compared with historical
ontrols using bare metal stents with a restenosis rate of
5.7% and a TLR of 8.1% (7 of 86). However, this study
howed discrepancies between patients treated with differ-
nt strategies using sirolimus-eluting stents. Indeed, there
as a slight but nonsignificant trend toward higher rates of
estenosis in patients treated with systematic side branch
tenting (28%) versus patients treated with provisional side
ranch stenting (18.7%). Overall, these results support a role
or the strategy used in the treatment of complex coronary
Up in Patients With Bifurcation Lesions
TVR
95% CI OR* 95% CI
043–1.474) 1.303 (1.095–1.552)
049–2.001) 1.586 (1.143–2.201)
076–2.459) 1.605 (1.050–2.453)
517–6.341) 2.970 (1.432–6.158)
081–3.059) 1.892 (1.109–3.226)
512–0.941) 0.680 (0.498–0.929)
361–0.771) — —
— 2.131 (1.393–3.261)
up.
; OR odds ratio. Other abbreviations as in Tables 4 and 5.llow-
ACE
(1.
(1.
(1.
(1.
(1.
(0.
(0.esions such as bifurcation lesions. This is corroborated by
t
T
N
t
d
d
i
S
s
r
i
S
(
r
s
i
a
o
c
c
i
t
r
S
t
a
l
a
c
d
o
i
C
o
b
h
s
a
s
e
c
R
C
d
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
612 Garot et al. JACC Vol. 46, No. 4, 2005
Outcome of Bifurcation Lesions PCI August 16, 2005:606–12he European Study of the Sirolimus-Eluting Stent in the
reatment of Patients with Long De Novo Lesions in Small
ative Coronary Arteries (E-SIRIUS) trial (19) suggesting
hat optimal outcomes with a potent therapy such as
rug-eluting stents are still operator-dependent and vali-
ated by the Canadian Study of the Sirolimus-Eluting Stent
n the Treatment of Patients with Long De Novo Lesions in
mall Native Coronary Arteries (C-SIRIUS) (20) that
ubtends a potential role of PCI technique itself in different
estenosis rates observed in SIRIUS (8.9%), the Random-
zed Comparison of a Sirolimus-Eluting Stent with a
tandard Stent for Coronary Revascularization (RAVEL)
0%), E-SIRIUS (5.9%), and C-SIRIUS (2.3%). More
ecently, restenosis was reported to be relatively low with
irolimus-eluting stents (7.9% of lesions), occurring mainly
n high-risk patients, in-stent, for long lesions, small vessels,
nd bifurcation lesions (21). In the present study, predictors
f MACE and TVR after PCI of bifurcation lesions are
onsistent with previous reports emphasizing the role of
linical (diabetes mellitus, prior CABG, history of transient
schemic attack, angina status) and procedural characteris-
ics (de novo lesions/restenosis, stents) in increasing MACE
ates after PCI of nonbifurcation lesions (22,23).
tudy limitations. This is a post-hoc analysis of a prospec-
ive, randomized trial, and it has the intrinsic limitations of
ny retrospective study. However, the study population is a
arge and contemporary interventional population with rel-
tively complete data and follow-up. Thus, some specific
haracteristics of bifurcation lesions and their PCI were not
escribed in detail, and their potential impact on the
utcome of patients may not have been taken into account
n the present analysis.
onclusions. Compared with nonbifurcation lesions, PCI
f bifurcation lesions is associated with higher rates of TVR
ut similar rates of death and MI at nine months. This
igher rate of TVR may be due in part to the “oculo-
tenotic” reflex observed in patients undergoing coronary
ngiography at nine-month follow-up in the angiographic
ubstudy. Further decreases in restenosis rates using drug-
luting stents and optimized strategies dedicated to bifur-
ation lesions need to be determined in future studies.
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